Despite the ebbing of the Ebola epidemic in West Africa, a Chinese firm says it will invest $315 million into a facility in Tianjin to mass produce an Ebola vaccine developed by a group out of China's Academy of Military Medical Sciences, Reuters reports. The facility, being built by Tianjin CanSino Biotechnology, will be finished between 2017 and 2018, the news service adds. Last December, the Chinese government approved the experimental vaccine for trials in an effort to compete with global leaders in the Ebola vaccine development space. More